GET DAILY SIGNALSOmnicell (OMCL) Delivers Q3 Profitability Beat Despite Slight Revenue Decline
Key Takeaways
- Omnicell reported third-quarter 2026 total revenue of $308 million, down 1% from $310.6 million a year earlier but above the high end of its own guidance range.
- Non-GAAP earnings per share (EPS) came in at $0.58, topping the roughly $0.42 consensus estimate by about 39% and up from $0.51 a year ago.
- GAAP net income reached $11.0 million, or $0.24 per diluted share, compared with $5.5 million, or $0.12 per share, in the prior-year quarter.
- Non-GAAP EBITDA (earnings before interest, taxes, depreciation, and amortization) rose to $45 million, exceeding the company's guidance range of $32 million to $37 million.
- Management raised its full-year 2026 non-GAAP EBITDA and EPS guidance while tightening revenue ranges, reflecting improved profitability and greater visibility.
- Shares moved higher after the results, although fourth-quarter revenue guidance came in below some analyst expectations.
- For additional context on this ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore the dedicated pages for Omnicell.
- To discover AI-driven trading ideas across the market, explore the Trending AI Robots page.
Earnings Context and Why It Matters
Omnicell focuses on healthcare technology for autonomous medication management, assisting hospitals and health systems with automating and connecting medication processes. Its results provide insight into hospital capital spending, demand for connected solutions, and the strength of recurring service and software revenue. After a solid first quarter, the company has stressed cost discipline and margin improvement even as revenue growth stays modest. The third quarter drew attention for indications that demand for the Titan XT hardware and OmniSphere cloud platform is converting into bookings and pipeline growth, with margins also benefiting from product and service mix.
Reported Results
For the quarter ended September 30, 2026, Omnicell posted total revenue of $308 million, down 1% from $310.6 million in the year-ago period. Product revenue fell to $173.1 million from $177.5 million, while service revenue increased to $134.8 million from $133.1 million. GAAP net income rose to $11.0 million, or $0.24 per diluted share, from $5.5 million, or $0.12 per share, a year earlier. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
On a non-GAAP basis, net income reached $27 million, or $0.58 per diluted share, up from $24 million, or $0.51 per share. Non-GAAP EBITDA totaled $45 million, above the prior guidance range of $32 million to $37 million and up from $41 million in the third quarter of 2025. Both revenue and profitability beat the high end of management guidance, and non-GAAP EPS exceeded the consensus estimate of roughly $0.42. Cash and equivalents stood near $315 million, with operating cash flow of $33 million.
Market Reaction and Investor Sentiment
The quarter highlighted a clear profitability beat supported by cost control and favorable mix. Shares rose modestly following the release. That said, fourth-quarter revenue guidance pointed to a year-over-year decline and landed below some analyst forecasts, which tempered enthusiasm. Investors appeared to balance the improved margin outlook and raised full-year profitability targets against the softer revenue trend. The response indicates the market is rewarding execution and cost management while staying cautious on near-term top-line growth during the platform transition.
Forward Outlook and Key Factors to Monitor
Omnicell guided fourth-quarter 2026 revenue to $295 million to $301 million, non-GAAP EBITDA of $30 million to $36 million, and non-GAAP EPS of $0.41 to $0.49. For the full year, it now projects revenue of $1.225 billion to $1.231 billion, non-GAAP EBITDA of $187 million to $193 million, and non-GAAP EPS of $2.48 to $2.56. Annual recurring revenue guidance tightened to $660 million to $670 million, while product bookings guidance of $425 million to $560 million was reiterated. I’m watching this closely as a sign of greater visibility.
Several items deserve attention in upcoming quarters. The commercial ramp of Titan XT and OmniSphere will indicate future product revenue trajectory through early shipments and adoption. Product bookings serve as a key leading indicator given the variable timing of hospital decisions. Margin sustainability remains in focus, as recent gains stem from efficiency and mix. Broader hospital capital spending and demand for medication automation solutions will also influence results. While profitability guidance improved, revenue growth continues to be a key question for the longer-term outlook.
Using AI Tools for Stock Analysis
When reviewing names like OMCL, I often rely on Tickeron’s AI Screener to quickly filter opportunities by technical patterns, fundamentals, and sector trends. It helps surface comparable ideas in healthcare technology without manual effort, adding useful context to traditional research. This approach has become a standard step in my process for identifying potential setups across the market.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
OMCL's RSI Oscillator peaks and leaves overbought zone
The 10-day RSI Oscillator for OMCL moved out of overbought territory on October 13, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 23 instances where the indicator moved out of the overbought zone. In 20 of the 23 cases the stock moved lower in the days that followed. This puts the odds of a move down at 87%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 45 of 58 cases where OMCL's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 78%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where OMCL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 78%.
OMCL broke above its upper Bollinger Band on October 23, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on September 24, 2026. You may want to consider a long position or call options on OMCL as a result. In 65 of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 73%.
OMCL moved above its 50-day moving average on October 06, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for OMCL crossed bullishly above the 50-day moving average on October 12, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 79%.
Following a +3.88% 3-day Advance, the price is estimated to grow further. Considering data from situations where OMCL advanced for three days, in 168 of 263 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.
The Aroon Indicator entered an Uptrend today. In 113 of 174 cases where OMCL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 65%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating steady price growth. OMCL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 75 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 87 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.302) is normal, around the industry mean (4.731). P/E Ratio (43.388) is within average values for comparable stocks, (13.055). OMCL's Projected Growth (PEG Ratio) (6.110) is slightly higher than the industry average of (2.133). Dividend Yield (0.000) settles around the average of (0.012) among similar stocks. P/S Ratio (1.199) is also within normal values, averaging (6.065).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OMCL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 97, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of automated solutions for hospital medication and supply management
Industry ServicestotheHealthIndustry
Advertisement